PlantForm welcomes biopharma industry veteran Bruce Clark to Board of Directors
GUELPH, Ont., September 27, 2022 — PlantForm Corporation announced today that Dr. Bruce Clark, the former CEO and President of Medicago, has joined PlantForm’s Board of Directors.
Clark has more than 30 years of experience in the biotech, pharmaceutical and related sectors, including senior management roles in scientific and regulatory affairs at Philip Morris International and Apotex Inc.
He led Quebec-based Medicago’s development and commercial strategies for the company’s COVID-19 vaccine, developed in collaboration with GlaxoSmithKline using a plant-based platform. In February 2022, Health Canada approved COVIFENZ®, the first authorized SARS-CoV-2 vaccine developed by a Canadian company and the first using a plant-based protein technology.
Clark’s appointment to PlantForm’s Board of Directors was announced at the company’s Annual General Meeting today.
“We are delighted to welcome Bruce to PlantForm’s Board of Directors,” said Dr. Don Stewart, PlantForm’s President and CEO. “He brings deep strategic, R&D and regulatory experience and his leadership and insights will strengthen our board as PlantForm advances its global strategy for plant-based protein drug development using our versatile vivoXPRESS® manufacturing platform.”
About PlantForm Corporation (www.plantformcorp.com)
PlantForm Corporation is a biopharmaceutical company focused on the ultra-low-cost production of specialty antibody and protein drugs using the proprietary vivoXPRESS® plant-based manufacturing platform. The vivoXPRESS plant expression system reduces biologic drug production costs by as much as 90% compared to standard mammalian cell systems. The platform is fast (drug production in as little as six weeks), versatile and easily scalable. PlantForm’s pipeline features an innovative antidote to ricin exposure, and biosimilar versions of the brand name biologic drugs Keytruda® and Lucentis.® Learn more.
For more information, please contact: